• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    11/12/24 9:38:01 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANNX alert in real time by email
    SC 13G/A 1 p24-3087sc13ga.htm ANNEXON, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
     

    Annexon, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    03589W102

    (CUSIP Number)
     

    September 30, 2024**

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☒ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    ** The original Schedule 13G and any amendment thereto filed with the Securities and Exchange Commission with respect to the shares of Common Stock held by the Reporting Persons (as defined in Item 2(a) hereof) prior to the date hereof was filed by Adage Capital Partners GP, L.L.C. (CIK 0001165408), which is no longer a Reporting Person with respect to the shares of Common Stock held by the Reporting Persons.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 03589W102

    13G/APage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.28%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. 03589W102

    13G/APage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.28%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. 03589W102

    13G/APage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,485,931 shares of Common Stock (including 645,786 shares of Common Stock issuable upon exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.28%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. 03589W102

    13G/APage 5 of 8 Pages

     

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Annexon, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      The Company’s principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:

     

      (i) Adage Capital Management, L.P., a Delaware limited partnership (“ACM”), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”), with respect to the shares of Common Stock and the shares of Common Stock issuable upon exercise of warrants directly held by ACP;
       
      (ii) Robert Atchinson (“Mr. Atchinson”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ACPLLC”), general partner of ACM, with respect to the shares of Common Stock and the shares of Common Stock issuable upon exercise of warrants directly held by ACP; and
       
      (iii) Phillip Gross (“Mr. Gross”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock and the shares of Common Stock issuable upon exercise of warrants directly held by ACP.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACM is a limited partnership organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER
      03589W102

     

     

    CUSIP No. 03589W102

    13G/APage 6 of 8 Pages

     

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) þ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.                                                           

     

    Item 4. OWNERSHIP
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentage set forth in this Schedule 13G/A is calculated based upon 105,653,962 shares of Common Stock outstanding as of August 8, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 12, 2024, and assumes the exercise of the warrants held by ACP.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      See Item 2(a).

     

     

    CUSIP No. 03589W102

    13G/APage 7 of 8 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION  
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 03589W102

    13G/APage 8 of 8 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 12, 2024

     

    ADAGE CAPITAL MANAGEMENT, L.P.  
    By: Adage Capital Partners LLC,  
    its general partner  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

    Get the next $ANNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANNX

    DatePrice TargetRatingAnalyst
    3/1/2024$11.00Neutral → Overweight
    JP Morgan
    12/21/2023$4.00 → $6.00Neutral → Buy
    BofA Securities
    10/30/2023$11.00Overweight
    Wells Fargo
    5/26/2023$8.00 → $3.00Buy → Neutral
    BofA Securities
    5/25/2023$19.00 → $9.00Overweight → Neutral
    JP Morgan
    9/16/2022$12.00Buy
    Jefferies
    9/9/2022$15.00Buy
    BTIG Research
    11/30/2021$40.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ANNX
    Financials

    Live finance-specific insights

    See more
    • Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

      Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the

      12/16/24 7:30:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

      Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and webcast today at 8:30 a.m. ET BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage platform of novel ther

      6/4/24 7:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

      BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon's website here. The dial-in number is 1-877-407-0784 (U.S./Canada) or 1-201-689-8560 (international). The conference ID for all callers is 13747058. The Call me™ link may be accessed here. Participants can use guest

      6/3/24 4:30:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Expands Board of Directors with Appointment of Commercial Executive William "BJ" Jones

      BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of  William "BJ" Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry. "We are thrilled to add BJ to our board of directors at this transformative time for Annexon," said Douglas Love, president and chief executive officer of Annexon. "His deep commercial expertise and proven experience

      1/10/25 8:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio

      BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the strengthening of its senior leadership team with the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial, Sunil B. Mehta, Pharm.D as senior vice president of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vice president of health economics and outcomes research. "We are excited to welcome Shikhar, Sunil and Myoung to the Annexon family as we prepare for commercial development of our flagship programs in Guillain-Barré Syndrome (

      9/3/24 8:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & CHIEF SCIENTIFIC OFFICER Artis Dean Richard was granted 44,963 shares, increasing direct ownership by 54% to 128,777 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      3/3/25 4:56:38 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Dananberg Jamie was granted 44,963 shares, increasing direct ownership by 134% to 78,442 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      3/3/25 4:55:35 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP & CHIEF FINANCIAL OFFICER Lew Jennifer was granted 44,963 shares, increasing direct ownership by 58% to 122,733 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      3/3/25 4:52:12 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Annexon Inc.

      10-Q - Annexon, Inc. (0001528115) (Filer)

      5/12/25 4:10:27 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Annexon, Inc. (0001528115) (Filer)

      5/12/25 4:05:15 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Annexon Inc.

      SCHEDULE 13G/A - Annexon, Inc. (0001528115) (Subject)

      4/30/25 10:54:11 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Carson William H. bought $17,056 worth of shares (3,200 units at $5.33), increasing direct ownership by 14% to 25,600 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      12/4/24 6:12:46 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carson William H. bought $19,104 worth of shares (3,200 units at $5.97), increasing direct ownership by 17% to 22,400 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      10/2/24 4:15:17 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carson William H. bought $17,536 worth of shares (3,200 units at $5.48), increasing direct ownership by 20% to 19,200 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      9/4/24 4:34:40 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 7:21:59 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 6:46:41 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 5:30:27 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

      First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient Populations New Analyses of Phase 3 Trial Highlight Tanruprubart's Early and Durable Treatment Effect and Improvement in Quality of Life in Patients with GBS BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye

      5/9/25 5:00:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

      Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on the neuroprotective effect of ANX007, including consistent benefits of C1q inhibition against inflammation and neuronal damage across diseases. The presentati

      5/7/25 8:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on April 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-executive employee received an option to purchase 105,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per sh

      4/16/25 4:05:18 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Annexon upgraded by JP Morgan with a new price target

      JP Morgan upgraded Annexon from Neutral to Overweight and set a new price target of $11.00

      3/1/24 7:27:25 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon upgraded by BofA Securities with a new price target

      BofA Securities upgraded Annexon from Neutral to Buy and set a new price target of $6.00 from $4.00 previously

      12/21/23 6:41:39 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Annexon with a new price target

      Wells Fargo initiated coverage of Annexon with a rating of Overweight and set a new price target of $11.00

      10/30/23 7:48:24 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care